AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21029621 — intervention group
Group type: EXPERIMENTAL
Intervention: Early intervention
Number of subjects: 815
Study 21029621 — intervention group
Group type: COMPARATOR
Intervention: Delayed intervention
Number of subjects: 815
Study 18432391 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-administered TLFB
Number of subjects: 70
Study 18432391 — intervention group
Group type: COMPARATOR
Intervention: Telephone-administered TLFB
Number of subjects: 70
Study 18777143 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel mental health service intervention
Number of subjects: 320
Study 14962967 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthrographic distension with saline and steroid
Number of subjects: 48
Study 14962967 — intervention group
Group type: COMPARATOR
Intervention: Placebo (arthrogram)
Number of subjects: 48
Study 12664761 — intervention group
Group type: EXPERIMENTAL
Intervention: Musculo‐skeletal medicine physician
Number of subjects: 1326
Study 12664761 — intervention group
Group type: COMPARATOR
Intervention: Conventional orthopaedic surgeon‐led service
Number of subjects: 1326
Study 9409315 — intervention group
Group type: EXPERIMENTAL
Intervention: Fradafiban (dose producing > 80% fibrinogen receptor occupancy)
Number of subjects: 18
Study 9409315 — intervention group
Group type: COMPARATOR
Intervention: Aspirin 330 mg
Number of subjects: 18
Study 9409315 — intervention group
Group type: EXPERIMENTAL
Intervention: Fradafiban
Number of subjects: 18
Study 8518408 — intervention group
Group type: EXPERIMENTAL
Intervention: Toremifene (TOR) 240 mg/day
Number of subjects: 66
Study 8518408 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen (TAM) 40 mg/day
Number of subjects: 66
Study 8518408 — intervention group
Group type: EXPERIMENTAL
Intervention: Second line TOR or TAM treatment
Number of subjects: 66
Study 3316874 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine
Number of subjects: 10
Study 11560537 — intervention group
Group type: EXPERIMENTAL
Intervention: QI-meds (n = 424 patients)
Number of subjects: 1356
Study 11560537 — intervention group
Group type: EXPERIMENTAL
Intervention: QI-therapy (n = 489 patients)
Number of subjects: 1356
Study 11560537 — intervention group
Group type: COMPARATOR
Intervention: Usual care (n = 443 patients)
Number of subjects: 1356
Study 30818320 — intervention group
Group type: EXPERIMENTAL
Intervention: Implant systems with the same surface and different design
Number of subjects: 21
Study 30563479 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle Intervention (12 months of primarily aerobic based exercise training)
Number of subjects: 142
Study 30563479 — intervention group
Group type: COMPARATOR
Intervention: Control (standard nephrological care)
Number of subjects: 142
Study 30563479 — intervention group
Group type: COMPARATOR
Intervention: CKD‐EPIcys
Number of subjects: 142
Study 30563479 — intervention group
Group type: COMPARATOR
Intervention: CKD‐EPIcr‐cys
Number of subjects: 142
Study 30563479 — intervention group
Group type: COMPARATOR
Intervention: MDRDcr
Number of subjects: 142
Study 26466947 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg add-on therapy to interferon β1b
Number of subjects: 154
Study 26466947 — intervention group
Group type: COMPARATOR
Intervention: Placebo add-on therapy to interferon β1b
Number of subjects: 154
Study 24784827 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment (IT)
Number of subjects: 2861
Study 24784827 — intervention group
Group type: COMPARATOR
Intervention: Routine care (RC)
Number of subjects: 2861
Study 22917991 — intervention group
Group type: EXPERIMENTAL
Intervention: Silorane-based resin composite (Filtek P90/Adhesive System‐3M ESPE)
Number of subjects: 33
Study 22917991 — intervention group
Group type: COMPARATOR
Intervention: Conventional methacrylate-based resin composite (Filtek P60/ Adper SE Plus‐3M ESPE)
Number of subjects: 33
Study 20218866 — intervention group
Group type: EXPERIMENTAL
Intervention: Buffy Coat-Platelet Rich Plasma (BC-PRP)
Number of subjects: 2
Study 20218866 — intervention group
Group type: COMPARATOR
Intervention: Control (non-PRP treated sites)
Number of subjects: 2
Study 17509693 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-session, protocol continuation-phase therapy for 8 months
Number of subjects: 79
Study 17509693 — intervention group
Group type: COMPARATOR
Intervention: Control cohort (stopped protocol treatment after the acute-phase)
Number of subjects: 79
Study 15129317 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporin alone (3.5 mg/kg/day) for three months
Number of subjects: 54
Study 15129317 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin (3.5 mg/kg/day) plus topical calcipotriol cream twice a day for three months
Number of subjects: 54
Study 12472705 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 0.5 mg x kg(‐1) with ketamine 1.8 mg x kg(‐1) (MK‐1)
Number of subjects: 79
Study 12472705 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 0.5 mg x kg(‐1) with ketamine 3 mg x kg(‐1) (MK‐2)
Number of subjects: 79
Study 12472705 — intervention group
Group type: COMPARATOR
Intervention: Midazolam 0.5 mg x kg(‐1) (MD)
Number of subjects: 79
Study 9659858 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine 5 mg/day
Number of subjects: 15
Study 9659858 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine 10 mg/day
Number of subjects: 15
Study 9659858 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine 15 mg/day
Number of subjects: 15
Study 9659858 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine 20 mg/day
Number of subjects: 15
Study 9659858 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine 30-40 mg/day
Number of subjects: 15
Study 9659858 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (all doses)
Number of subjects: 15
Study 9659858 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine 10-20 mg/day
Number of subjects: 15
Study 9659858 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine 30 mg/day and higher
Number of subjects: 15
Study 8134224 — intervention group
Group type: EXPERIMENTAL
Intervention: DTaP
Number of subjects: 165
Study 8134224 — intervention group
Group type: COMPARATOR
Intervention: DTwP
Number of subjects: 165
Study 2594924 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg clonidine
Number of subjects: 6
Study 2594924 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg yohimbine
Number of subjects: 6
Study 2594924 — intervention group
Group type: COMPARATOR
Intervention: Placebo (lactose)
Number of subjects: 6
Study 29110996 — intervention group
Group type: EXPERIMENTAL
Intervention: PAC burden (number per hour) assessed by 24‐hour ambulatory ECG monitoring
Number of subjects: 938
Study 29110996 — intervention group
Group type: COMPARATOR
Intervention: Baseline PAC burden
Number of subjects: 938
Study 29110996 — intervention group
Group type: COMPARATOR
Intervention: PVC burden
Number of subjects: 938
Study 26110890 — intervention group
Group type: EXPERIMENTAL
Intervention: 1‐month weight loss (WL) of 2‐4%
Number of subjects: 2290
Study 26110890 — intervention group
Group type: EXPERIMENTAL
Intervention: 1‐month weight loss (WL) of >4%
Number of subjects: 2290
Study 26110890 — intervention group
Group type: EXPERIMENTAL
Intervention: 2‐month weight loss (WL) of 3‐6%
Number of subjects: 2290
Study 26110890 — intervention group
Group type: EXPERIMENTAL
Intervention: 2‐month weight loss (WL) of >6%
Number of subjects: 2290
Study 23307281 — intervention group
Group type: EXPERIMENTAL
Intervention: MenACWY-TT
Number of subjects: 100
Study 23307281 — intervention group
Group type: COMPARATOR
Intervention: MenC-CRM197
Number of subjects: 100
Study 21775918 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusion with 20 mg of nafamostat mesilate (group B)
Number of subjects: 595
Study 21775918 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusion with 50 mg of nafamostat mesilate (group C)
Number of subjects: 595
Study 21775918 — intervention group
Group type: COMPARATOR
Intervention: Control group (group A)
Number of subjects: 595
Study 21775918 — intervention group
Group type: EXPERIMENTAL
Intervention: Nafamostat mesilate (20 mg) in low-risk patients
Number of subjects: 595
Study 21775918 — intervention group
Group type: COMPARATOR
Intervention: Control in low-risk patients
Number of subjects: 595
Study 21775918 — intervention group
Group type: EXPERIMENTAL
Intervention: Nafamostat mesilate (50 mg) in low-risk patients
Number of subjects: 595
Study 21775918 — intervention group
Group type: EXPERIMENTAL
Intervention: Nafamostat mesilate (20 mg) in high-risk patients
Number of subjects: 595
Study 21775918 — intervention group
Group type: EXPERIMENTAL
Intervention: Nafamostat mesilate (50 mg) in high-risk patients
Number of subjects: 595
Study 21775918 — intervention group
Group type: COMPARATOR
Intervention: Control in high-risk patients
Number of subjects: 595
Study 18620801 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate alone
Number of subjects: 73
Study 18620801 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline alone
Number of subjects: 73
Study 18620801 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of topiramate and amitriptyline
Number of subjects: 73
Study 18620801 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 73
Study 16407642 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C and E supplementation (500 mg slow-release vitamin C and 272 IU vitamin E for 4 weeks)
Number of subjects: 19
Study 16407642 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen (HBO) treatment (100% O2, 2.4 bar, 131 min)
Number of subjects: 19
Study 16407642 — intervention group
Group type: COMPARATOR
Intervention: Normoatmospheric protocol (21% O2, 1.0 bar, 131 min)
Number of subjects: 19
Study 14645636 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy with concurrent administration of cisplatin
Number of subjects: 547
Study 14645636 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction cisplatin plus fluorouracil followed by radiotherapy
Number of subjects: 547
Study 14645636 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 547
Study 14645636 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy with concurrent cisplatin
Number of subjects: 547
Study 14645636 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent radiotherapy and cisplatin
Number of subjects: 547
Study 10589807 — intervention group
Group type: EXPERIMENTAL
Intervention: Test Sc/RP (scaling and root planing performed from approximately 1 mm coronal to the probeable pocket)
Number of subjects: 7
Study 10589807 — intervention group
Group type: COMPARATOR
Intervention: Control Sc/RP (scaling and root planing performed at the bottom of the probeable pocket)
Number of subjects: 7
Study 10589807 — intervention group
Group type: COMPARATOR
Intervention: Control Sc/RP
Number of subjects: 7
Study 10589807 — intervention group
Group type: EXPERIMENTAL
Intervention: Test Sc/RP
Number of subjects: 7
Study 9167419 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin
Number of subjects: 64
Study 2020050 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal sonography
Number of subjects: 175
Study 2020050 — intervention group
Group type: COMPARATOR
Intervention: Abdominal sonography
Number of subjects: 175
Study 7060821 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg atenolol
Number of subjects: 21
Study 7060821 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg penbutolol
Number of subjects: 21
Study 7060821 — intervention group
Group type: COMPARATOR
Intervention: Combination therapy (propranolol or metoprolol with chlorthalidone)
Number of subjects: 21
Study 30830964 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine
Number of subjects: 30
Study 30830964 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 30
Study 30830964 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine-3-glucuronide (M3G)
Number of subjects: 30
Study 30830964 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine-6-glucuronide (M6G)
Number of subjects: 30
Study 27989501 — intervention group
Group type: EXPERIMENTAL
Intervention: DFA-02 gel (gentamicin 16.8 mg/mL and vancomycin 18.8 mg/mL)
Number of subjects: 445
Study 27989501 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 445
Study 27989501 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SOC)
Number of subjects: 445
Study 27989501 — intervention group
Group type: EXPERIMENTAL
Intervention: DFA-02 gel
Number of subjects: 445
Study 27989501 — intervention group
Group type: COMPARATOR
Intervention: SOC
Number of subjects: 445
Study 27057883 — intervention group
Group type: EXPERIMENTAL
Intervention: Hole ICL
Number of subjects: 32
Study 27057883 — intervention group
Group type: COMPARATOR
Intervention: Conventional ICL
Number of subjects: 32
Study 25084280 — intervention group
Group type: EXPERIMENTAL
Intervention: AP (Armolipid Plus)
Number of subjects: 102
Study 25084280 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study 22744524 — intervention group
Group type: EXPERIMENTAL
Intervention: Smart brace
Number of subjects: 12
Study 22744524 — intervention group
Group type: COMPARATOR
Intervention: Standard rigid brace
Number of subjects: 12
Study 19574761 — intervention group
Group type: EXPERIMENTAL
Intervention: Music therapy
Number of subjects: 0
Study 17887946 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast food Mediterranean-type diet for 4 weeks (groups A and B)
Number of subjects: 45
Study 17887946 — intervention group
Group type: COMPARATOR
Intervention: Regular diet (group C)
Number of subjects: 45
Study 15151774 — intervention group
Group type: EXPERIMENTAL
Intervention: Stent implantation with balloon predilatation
Number of subjects: 100
Study 15151774 — intervention group
Group type: COMPARATOR
Intervention: Direct stenting without balloon predilatation
Number of subjects: 100
Study 11153970 — intervention group
Group type: EXPERIMENTAL
Intervention: Graded exposure in vivo treatment
Number of subjects: 4
Study 11153970 — intervention group
Group type: COMPARATOR
Intervention: Graded activity
Number of subjects: 4
Study 9471067 — intervention group
Group type: EXPERIMENTAL
Intervention: Savage technique
Number of subjects: 40
Study 9471067 — intervention group
Group type: COMPARATOR
Intervention: Tajima technique
Number of subjects: 40
Study 9471067 — intervention group
Group type: COMPARATOR
Intervention: Halsted technique
Number of subjects: 40
Study 9471067 — intervention group
Group type: COMPARATOR
Intervention: Silfverskiold technique
Number of subjects: 40
Study 8197551 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative radiotherapy (7 Gy in one fraction)
Number of subjects: 84
Study 8197551 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy (17.5 Gy in five fractions of 3.5 Gy each)
Number of subjects: 84
Study 8197551 — intervention group
Group type: COMPARATOR
Intervention: Preoperative group
Number of subjects: 84
Study 8197551 — intervention group
Group type: COMPARATOR
Intervention: Postoperative group
Number of subjects: 84
Study 3371389 — intervention group
Group type: EXPERIMENTAL
Intervention: metoprolol CR (100 mg)
Number of subjects: 12
Study 3371389 — intervention group
Group type: EXPERIMENTAL
Intervention: metoprolol SR (100 mg)
Number of subjects: 12
Study 31119512 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based social skills interventions (GSSIs) for individuals with autism spectrum disorder (ASD)
Number of subjects: 17
Study 27651514 — intervention group
Group type: EXPERIMENTAL
Intervention: HYD intact 60 mg
Number of subjects: 40
Study 27651514 — intervention group
Group type: EXPERIMENTAL
Intervention: HYD chewed 60 mg
Number of subjects: 40
Study 27651514 — intervention group
Group type: EXPERIMENTAL
Intervention: HYD milled to fine particles 60 mg
Number of subjects: 40
Study 27651514 — intervention group
Group type: COMPARATOR
Intervention: Hydrocodone solution 60 mg
Number of subjects: 40
Study 27651514 — intervention group
Group type: EXPERIMENTAL
Intervention: Pupillometry measurements with HYD intact and HYD chewed
Number of subjects: 40
Study 27651514 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocodone solution, HYD fine particles, HYD chewed, and HYD intact
Number of subjects: 40
Study 27651514 — intervention group
Group type: EXPERIMENTAL
Intervention: Safety measures
Number of subjects: 40
Study 25782852 — intervention group
Group type: EXPERIMENTAL
Intervention: True acupuncture
Number of subjects: 76
Study 25782852 — intervention group
Group type: COMPARATOR
Intervention: Placebo acupuncture (sham acupuncture)
Number of subjects: 76
Study 23668896 — intervention group
Group type: EXPERIMENTAL
Intervention: Skill-building intervention
Number of subjects: 0
Study 23668896 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control condition
Number of subjects: 0
Study 21427643 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy (CBT), up to 10 sessions for 12 weeks
Number of subjects: 76
Study 21427643 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care (regular, brief telephone calls, and referrals to primary care provider as needed)
Number of subjects: 76
Study 18791817 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with GI problems (22.7% of the sample)
Number of subjects: 172
Study 18791817 — intervention group
Group type: COMPARATOR
Intervention: Children without GI problems
Number of subjects: 172
Study 18791817 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with GI problems
Number of subjects: 172
Study 17045826 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone (10 mg bd)
Number of subjects: 16
Study 17045826 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilomilast (15 mg bd)
Number of subjects: 16
Study 17045826 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 15266207 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk assessment program with genetic counseling about lifetime risk based on gender, family history, and APOE genotype.
Number of subjects: 375
Study 11511128 — intervention group
Group type: EXPERIMENTAL
Intervention: Jobs portrayed with male workers
Number of subjects: 0
Study 11511128 — intervention group
Group type: COMPARATOR
Intervention: Jobs portrayed with female workers
Number of subjects: 0
Study 11511128 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel jobs
Number of subjects: 0
Study 9304515 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodality therapy (chemotherapy and irradiation)
Number of subjects: 0
Study 8492199 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg of methylprednisolone given intravenously before operation in combination with orally administered rapid‐release and sustained‐release diclofenac preparations
Number of subjects: 0
Study 8492199 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac alone
Number of subjects: 0
Study 2963645 — intervention group
Group type: EXPERIMENTAL
Intervention: Eleutherococcus senticosus extract (10 ml, ethanolic preparation, 3 times daily for 4 weeks)
Number of subjects: 36
Study 2963645 — intervention group
Group type: COMPARATOR
Intervention: Placebo (additional wine with identical ethanol concentration)
Number of subjects: 36
Study 2702236 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous epinephrine
Number of subjects: 0
Study 2702236 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous terbutaline
Number of subjects: 0
Study 31561336 — intervention group
Group type: EXPERIMENTAL
Intervention: Knee-length compression stockings with an interface pressure of 18-21 mmHg (stocking type 1)
Number of subjects: 19
Study 31561336 — intervention group
Group type: COMPARATOR
Intervention: Knee-length compression stockings with an interface pressure of 23-32 mmHg (stocking type 2)
Number of subjects: 19
Study 28899418 — intervention group
Group type: EXPERIMENTAL
Intervention: Web course plus CPR training
Number of subjects: 432
Study 28899418 — intervention group
Group type: COMPARATOR
Intervention: CPR training only (control)
Number of subjects: 432
Study 25463964 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation intentions using a volitional help sheet
Number of subjects: 243
Study 25463964 — intervention group
Group type: COMPARATOR
Intervention: General information about the risks of speeding (Control)
Number of subjects: 243
Study 25463964 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation intentions
Number of subjects: 243
Study 23918578 — intervention group
Group type: EXPERIMENTAL
Intervention: Meloxicam + Pregabalin
Number of subjects: 89
Study 23918578 — intervention group
Group type: COMPARATOR
Intervention: Meloxicam
Number of subjects: 89
Study 23918578 — intervention group
Group type: COMPARATOR
Intervention: Pregabalin
Number of subjects: 89
Study 22015120 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin-to-skin care (SSC)
Number of subjects: 183
Study 18929499 — intervention group
Group type: EXPERIMENTAL
Intervention: GH 1mg/m(2)/day
Number of subjects: 292
Study 18929499 — intervention group
Group type: COMPARATOR
Intervention: Control group (short young SGA adults)
Number of subjects: 292
Study 17127777 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of ipratropium bromide and salbutamol
Number of subjects: 60
Study 17127777 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol alone
Number of subjects: 60
Study 14730405 — intervention group
Group type: EXPERIMENTAL
Intervention: C(15)O(2) or H(2)(15)O, (15)O‐labelled carbon monoxide (C(15)O) and (15)O‐labelled oxygen ((15)O(2))
Number of subjects: 70
Study 11391739 — intervention group
Group type: EXPERIMENTAL
Intervention: N‐0923 TDS 33.5 mg
Number of subjects: 85
Study 11391739 — intervention group
Group type: EXPERIMENTAL
Intervention: N‐0923 TDS 67 mg
Number of subjects: 85
Study 11391739 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85
Study 9164591 — intervention group
Group type: EXPERIMENTAL
Intervention: d-amphetamine 10 mg in SOC
Number of subjects: 42
Study 9164591 — intervention group
Group type: EXPERIMENTAL
Intervention: d-amphetamine 20 mg
Number of subjects: 42
Study 9164591 — intervention group
Group type: EXPERIMENTAL
Intervention: d-amphetamine (10 or 20 mg)
Number of subjects: 42
Study 9164591 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 8485430 — intervention group
Group type: EXPERIMENTAL
Intervention: Low alcohol (0.025% BAC)
Number of subjects: 0
Study 8485430 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate alcohol (0.05% BAC)
Number of subjects: 0
Study 8485430 — intervention group
Group type: COMPARATOR
Intervention: No alcohol
Number of subjects: 0
Study 3618993 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (received prerecorded audio tape with suggestions)
Number of subjects: 30
Study 3618993 — intervention group
Group type: COMPARATOR
Intervention: Control group (did not receive the audio tape)
Number of subjects: 30